Navigation Links
StemCyte Locates East Coast Operations in New Jersey
Date:5/1/2008

Cell Therapy Company's Move Driven by Commitment of Governor and

Collaboration with Leading Stem Cell Researcher

EWING, N.J., May 1 /PRNewswire/ -- StemCyte Inc. today announced that it has located its East Coast operations in Ewing, N.J.

The move, which was supported by a Business Employment Incentive Program (BEIP) grant through the New Jersey Economic Development Authority, puts StemCyte's executives in close proximity to one of the company's collaborators: world-renowned spinal cord injury researcher Wise Young, M.D., Ph.D., at Rutgers University.

"The research being done by Dr. Young at Rutgers is top-notch," said Kenneth J. Giacin, chairman and chief executive officer of StemCyte. "In addition, Governor Corzine's plan for developing New Jersey as an active hub for stem cell research and therapeutics development was an important reason for our decision to move our East Coast operations to the state. We're pleased to become an integral part of New Jersey's life sciences community with our focus on therapies derived from umbilical cord blood."

In addition to the New Jersey location, StemCyte's operations are in California and Taiwan. The company is also developing StemCyte India Therapeutics in collaboration with Apollo Hospitals and Cadila Pharmaceuticals.

About StemCyte Inc.

StemCyte Inc. is a global cell therapy company with a focus on umbilical cord blood stem cells. Since 2001, the company's stem cell products have been used to successfully treat more than 600 patients suffering from life- threatening diseases and conditions. StemCyte also has a leadership position in the development of new cell therapies in high growth areas with the greatest clinical need. The company is accredited by AABB (formerly the American Association of Blood Banks) and Foundation for the Accreditation of Cellular Therapy (FACT). For more information, visit http://www.stemcyte.com.

StemCyte Media Contacts:

Russo Partners LLC

Ian Stone

(619) 814-3510

ian.stone@russopartnersllc.com

David Schull

(212) 845-4271

david.schull@russopartnersllc.com


'/>"/>
SOURCE StemCyte Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Millstone Medical Outsourcing Relocates Memphis Distribution Center Within 72 Hours of Tornado Disaster
2. Caliper Life Sciences Reports West Coast Consolidation of Operations
3. Phlo Affiliate to Launch AQUISS(TM) on East Coast
4. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
5. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
6. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
7. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
8. Biopure Operations Compliant With U.K. Manufacturing Guidelines
9. Genta Restructures Operations to Focus on Priority Initiatives
10. NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations
11. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , Feb. 27, 2017 Fluxion Biosciences announced ... has been appointed as a Certified Service ... IsoFlux system will be used in Genetracer Biotech,s novel ... lung and colon cancer, with plans to move to ... is utilizing Fluxion,s IsoFlux System to isolate, recover, and ...
(Date:2/27/2017)... URBANDALE, Iowa (PRWEB) , ... February 27, 2017 , ... ... one of only a few in the Midwest offering premix services and private label ... poultry feed for laying hens, according Jos Zamzow, chief operating officer of Dynamite Marketing, ...
(Date:2/25/2017)... ... February 25, 2017 , ... The ... in an ongoing effort to create meaningful change by increasing communication, partnerships and ... emphasis on consumers and patients’ mental health well-being. , Both organizations are dedicated ...
(Date:2/24/2017)... ... 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, ... Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ... to deliver therapeutic levels of olanzapine for a period of 3 months., “We are ...
Breaking Biology Technology:
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm Reports ... the laboratory use of nuclear magnetic resonance spectroscopy ... end-users and profiled current practices, developments, trends and ... well as growth and opportunities. These areas include ... NMR instruments, needs and innovation requirements, hyphenated NMR ...
(Date:1/23/2017)... -- The latest mobile market research from Acuity Market Intelligence ... quarterly average price of a biometric smartphone decreased from ... There are now 120 sub-$150 models on the market ... 28 a year ago at an average price of ... , Acuity Market Intelligence Principal, "Biometric Smartphones are a ...
(Date:1/19/2017)... PORTLAND, Oregon and PUNE, India , January 19, ... Market Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - ... 2022, growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... share owing to high-level security for both public and private sectors. ... ...
Breaking Biology News(10 mins):